Targeting endogenous transforming growth factor β receptor signaling in Smad4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5200-5211

  Subramanian, Gayathri ^a   Schwarz, Roderich E ^a   Higgins, Linda ^b   McEnroe, Glenn ^b   Chakravarty, Sarvajit ^b   Dugar, Sundeep ^b   Reiss, Michael ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b SCIOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA6 INTEGRIN; F ACTIN; INTEGRIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUTRALIZING ANTIBODY; NPC 37282; PROTEIN KINASE INHIBITOR; SD 093; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL CYCLE; CELL SURFACE; CONTROLLED STUDY; DEPHOSPHORYLATION; DISEASE COURSE; DOSE TIME EFFECT RELATION; HOMEOSTASIS; HUMAN; HUMAN CELL; PANCREAS CARCINOMA; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING;

ACTIVIN RECEPTORS, TYPE I; ANTIGENS, NEOPLASM; CADHERINS; CELL MOVEMENT; DNA-BINDING PROTEINS; ENZYME INHIBITORS; GENE DELETION; HUMANS; INTEGRINS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PHENOTYPE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 3442894138     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0018     Document Type: Article

References (87)

1. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor beta and its role in oncogenesis. Crit Rev Oncog 1993;4:493-540.
2. Reiss M. TGF-beta and cancer. Microbes Infect 1999;1:1327-47.
3. Barcellos-Hoff MH. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat Res 1998;150:S109-20.
4. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999;112:4557-68.
5. Dumont N, Arteaga CL. The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGF-beta. Differentiation 2002;70:574-82.
6. Piek E, Roberts AB. Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. Adv Cancer Res 2001;83:1-54.
7. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 2001;7:2931-40.
8. Akhurst RJ. TGF-beta antagonists: why suppress a tumor suppressor? J Clin Investig 2002;109:1533-6.
9. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Investig 2002;109:1607-15.
10. Massagué J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91.
11. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué, J. Mechanism of activation of the TGF-beta receptor. Nature (Lond.) 1994;370:341-7.
12. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002;7:1191-204.
13. Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 1997;272:27678-85.
14. Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, Heldin CH. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 1997;272:28107-15.
15. Pierreux CE, Nicolas FJ, Hill CS. Transforming growth factor-beta-independent shuttling of Smad4 between the cytoplasm and nucleus. Mol Cell Biol 2000;20:9041-54.
16. Xu L, Kang Y, Col S, Massague J. Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGF-beta signaling complexes in the cytoplasm and nucleus. Mol Cell 2002;10:271-82.
17. Inman GJ, Nicolas FJ, Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell 2002;10:283-94.
18. Wu JW, Hu M, Chai J, et al. Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. Mol Cell 2001;8:1277-89.
19. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000;19:1745-54.
20. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000;12:235-43.
21. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA - Cancer J Clin 2003;53:5-26.
22. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor-beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998;58:5329-32.
23. Villanueva A, Garcia C, Paules AB, et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998;17:1969-78.
24. Jonson T, Gorunova L, Dawiskiba S, et al. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer. Genes Chromosomes Cancer 1999;24:62-71.
25. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Wash. DC) 1996;271:350-3.
26. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30.
27. Hahn SA, Bartsch D, Schroers A, et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998;58:1124-6.
28. Dai JL, Turnacioglu KK, Schutte M, Sugar AY, Kern SE. Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res 1998;58:4592-7.
29. Xu J, Attisano L. Mutations in the tumor suppressors smad2 and smad4 inactivate transforming growth factor-beta signaling by targeting smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2000;97:4820-5.
30. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-6.
31. Tascilar M, Skinner HG, Rosty C, et al. The Smad4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001;7:4115-21.
32. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189-95.
33. Lu Z, Friess H, Graber HU, et al. Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997;42:2054-63.
34. Jonson T, Albrechtsson E, Axelson J, et al. Altered expression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas. Int J Oncol 2001;19:71-81.
35. Baldwin RL, Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors 1993;8:23-34.
36. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-7.
37. Kleeff J, Korc M. Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells. J Biol Chem 1998;273:7495-500.
38. Nicolas FJ, Hill CS. Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 2003;22:3698-711.
39. Baldwin RL, Friess H, Yokoyama M, et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996;67:283-8.
40. Wagner M, Kleeff J, Lopez ME, Bookman I, Massaque J, Korc M. Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer 1998;78:255-60.
41. Kim SJ, Im YH, Markowitz SD, Bang YJ. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 2000;11:159-68.
42. de Winter JP, Roelen BA, ten Dijke P, van der Burg B, van den Eijnden-van Raaij AJ. DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 1997;14:1891-9.
43. Zhang Y, Feng X-H, Wu R-Y, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature (Lond.) 1996;383:168-72.
44. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature (Lond.) 1996;383:832-6.
45. Zhou S, Buckhaults P, Zawel L, et al. Targeted deletion of Smad4 shows it is required for transforming growth factor-beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA 1998;95:2412-6.
46. Dai JL, Schutte M, Bansal RK, Wilentz RE, Sugar AY, Kern SE. Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Mol Carcinog 1999;26:37-43.
47. Sirard C, Kim S, Mirtsos C, et al. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor-beta-related signaling. J Biol Chem 2000;275:2063-70.
48. Jonson T, Heidenblad M, Hakansson P, et al. Pancreatic carcinoma cell lines with SMAD4 inactivation show distinct expression responses to TGFB1. Genes Chromosomes Cancer 2003;36:340-52.
49. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of transforming growth factor-beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
50. Owens RB, Smith HS, Nelson-Rees WA, Springer EL. Epithelial cell cultures from normal and cancerous human tissues. J Natl Cancer Inst (Bethesda) 1976;56:843-9.
51. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 1977;19:218-35.
52. Chen WH, Horoszewicz JS, Leong SS, et al. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro 1982;18:24-34.
53. Tan MH, Nowak NJ, Loor R, et al. Characterization of a new primary human pancreatic tumor line. Cancer Investig 1986;4:15-23.
54. Schoumacher RA, Ram J, Iannuzzi MC, et al. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci USA 1990;87:4012-6.
55. Dahiya R, Kwak KS, Byrd JC, Ho S, Yoon WH, Kim YS. Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-1 mucin gene. Cancer Res 1993;53:1437-43.
56. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J. The TGF-beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell 2001;8:671-82.
57. Ge R, Rajeev V, Subramanian G, et al. Selective inhibitors of transforming growth factor-beta type I receptor kinase block cellular transforming growth factor-beta signaling. Biochem Pharmacol 2004;68:41-50.
58. Yan W, Vellucci VF, Reiss M. Smad protein expression and activation in transforming growth factor-beta refractory human squamous cell carcinoma cells. Oncol Res 2000;12:157-67.
59. Eickelberg O, Centrella M, Reiss M, Kashgarian M, Wells RG. Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem 2002;277:823-9.
60. Coutts A, Chen G, Stephens N, et al. Release of biologically active TGF-beta from airway smooth muscle cells induces autocrine synthesis of collagen. Am J Physiol Lung Cell Mol Physiol 2001;280:L999-1008.
61. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994;216:276-84.
62. Simeone DM, Pham T, Logsdon CD. Disruption of TGF-beta signaling pathways in human pancreatic cancer cells. Ann Surg 2000;232:73-80.
63. Reiss M. Transforming growth factor-beta and cancer: a love-hate relationship? Oncol Res 1997;9:447-57.
64. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12:22-9.
65. Yu L, Hebert MC, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 2002;21:3749-59.
66. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGF-beta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci 2002;115:3193-206.
67. Kaneko K, Satoh K, Masamune A, Satoh A, Shimosegawa T. Expression of ROCK-1 in human pancreatic cancer: its down-regulation by morpholino oligo antisense can reduce the migration of pancreatic cancer cells in vitro. Pajicreas 2002;24:251-7.
68. Brown K, Bhowmick NA. Linking TGF-beta-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160(ROCK) signaling. Cell Cycle 2004;3:408-10.
69. Bhowmick NA, Ghiassi M, Aakre M, Brown K, Singh V, Moses HL. TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci USA 2003;100:15548-53.
70. Brodin G, Ahgren A, ten Dijke P, Heldin CH, Heuchel R. Efficient TGF-(beta) induction of the Smad7 gene requires co-operation between AP-1, Sp1 and Smad proteins on the mouse smad7 promoter. J Biol Chem 2000;275:29023-30.
71. Mori Y, Chen SJ, Varga J. Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-beta. Exp Cell Res 2000;258:374-83.
72. 8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 2002;157:493-507.
73. 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319-28.
74. 6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature (Lond.) 2003;422:169-73.
75. Xie W, Kim D, Haffty BG, Rimm DL, Reiss M. Frequent alterations of Smad signaling in human head-&-neck squamous cell carcinomas: a tissue microarray analysis. Oncology Res 2003;14:61-73.
76. Bellone G, Turletti A, Artusio E, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999;155:537-47.
77. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 2001;93:204-11.
78. Rowland-Goldsmith MA, Maruyama H, Matsuda K, et al. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 2002;1:161-7.
79. Schlingensiepen KH, Jachimczak P, Graf K, et al. Suppression of TGF-beta2 in pancreatic cancer by antisense oligonucteotide AP 12009: in vitro efficacy data. Proc Am Assoc Cancer Res 2003;44:1458.
80. Teraoka H, Sawada T, Yamashita Y, et al. TGF-beta1 promotes liver metastasis of pancreatic cancer by modulating the capacity of cellular invasion. Int J Oncol 2001;19:709-15.
81. Giehl K, Seidel B, Gierschik P, Adler G, Menke A. TGF-beta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene 2000;19:4531-41.
82. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002;4:487-94.
83. Suwa H, Ohshio G, Imamura T, et al. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 1998;77:147-52.
84. Ellenrieder V, Hendler SF, Boeck W, et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001;61:4222-8.
85. Chen RH, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science (Wash. DC) 1993;260:1335-8.
86. Massague J, Chen Y-G. Controlling TGF-β signaling. Genes Dev 2000;14:627-44.
87. Fink SP, Mikkola D, Willson JK, Markowitz S. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 2003;22:1317-23.